Highly active antiretroviral therapy and human immunodeficiency virus encephalitis

Annals of Neurology

Volumn 57, Issue 6, 2005, Pages 795-803

  Cook, Jennifer E ^a   Dasgupta, Somsankar ^b   Middaugh, Lawrence D ^a   Terry, Elaine C ^a   Gorry, Paul R ^c,d   Wesselingh, Steven L ^c,d   Tyor, William R ^a,e  

^a MEDICAL UNIVERSITY OF SOUTH CAROLINA   (United States)

^b MEDICAL COLLEGE OF GEORGIA   (United States)

^c MACFARLANE BURNET INSTITUTE FOR MEDICAL RESEARCH AND PUBLIC HEALTH   (Australia)

^d MONASH UNIVERSITY   (Australia)

^e CSB 310 ^*  (United States)

Author keywords

[No Author keywords available]

Indexed keywords

INDINAVIR; LAMIVUDINE; ZIDOVUDINE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; ASTROCYTOSIS; CLINICAL FEATURE; CONTROLLED STUDY; DRUG ISOLATION; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MALE; MONOCYTE; MOUSE; NEUROPATHOLOGY; NONHUMAN; PRIORITY JOURNAL; SCID MOUSE; VIRUS ENCEPHALITIS; VIRUS LOAD;

AIDS DEMENTIA COMPLEX; ANIMALS; ANTI-HIV AGENTS; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; BRAIN; DISEASE MODELS, ANIMAL; DRUG THERAPY, COMBINATION; HIV PROTEASE INHIBITORS; HUMANS; INDINAVIR; LAMIVUDINE; MALE; MICE; MICE, SCID; MONOCYTES; VIRAL LOAD; ZIDOVUDINE;

EID: 20444395039     PISSN: 03645134     EISSN: None     Source Type: Journal    
DOI: 10.1002/ana.20479     Document Type: Article

References (39)

1. McArthur JC, Hoover DR, Bacellar H, et al. Dementia in AIDS patients: incidence and risk factors. Multicenter AIDS Cohort Study. Neurology 1993;43:2245-2252.
2. Navia BA, Jordan BD, Price RW. The AIDS dementia complex: I. Clinical features. Ann Neurol 1986;19:517-524.
3. Tyor WR, Glass JD, Griffin JW, et al. Cytokine expression in the brain during the acquired immunodeficiency syndrome. Ann Neurol 1992;31:349-360.
4. Wesselingh SL, Power C, Glass JD, et al. Intracerebral cytokine messenger RNA expression in acquired immunodeficiency syndrome dementia. Ann Neurol 1993;33:576-582.
5. Lipton S, Gendelman HE. Dementia associated with the acquired immunodeficiency syndrome. N Engl J Med 1995;332:934-940.
6. Power C, McArthur JC, Nath A, et al. Neuronal death induced by brain-derived human immunodeficiency virus type 1 envelope genes differs between demented and nondemented AIDS patients. J Virol 1998;72:9045-9053.
7. Glass JD, Fedor H, Wesselingh SL, McArthur JC. Immunocytochemical quantitation of human immunodeficiency virus in the brain: correlations with dementia. Ann Neurol 1995;38:755-762.
8. Johnson RT, Glass JD, McArthur JC, Chesebro BW. Quantitation of human immunodeficiency virus in brains of demented and nondemented patients with acquired immunodeficiency syndrome. Ann Neurol 1996;39:392-395.
9. Wiley CA, Achim C. Human immunodeficiency virus encephalitis is the pathological correlate of dementia in acquired immunodeficiency syndrome. Ann Neurol 1994;36:673-676.
10. Dore GJ, Correll PK, Li Y, et al. Changes to AIDS dementia complex in the era of highly active antiretroviral therapy. AIDS 1999;13:1249-1253.
11. Limoges J, Poluektova L, Ratanasuwan W, et al. The efficacy of potent anti-retroviral drug combinations tested in a murine model of HIV-1 encephalitis. Virology 2001;281:21-34.
12. Neuenburg JK, Brodt HR, Herndier BG, et al. HIV-related neuropathology, 1985 to 1999: rising prevalence of HIV encephalopathy in the era of highly active antiretroviral therapy. JAIDS 2002;31:171-177.
13. McArthur JC, Haughey N, Gartner S, et al. Human immunodeficiency virus-associated dementia: an evolving disease. J Neurovirol 2003;9:205-221.
14. Letendre SL, McCutchan JA, Childers ME, et al. Enhancing antiretroviral therapy for human immunodeficiency virus cognitive disorders. Ann Neurol 2004;56:416-426.
15. Limoges J, Persidsky Y, Poluektova L, et al. Evaluation of antiretroviral drug efficacy for HIV-1 encephalitis in SCID mice. Neurology 2000;54:379-389.
16. Blankson JN, Persaud D, Siliciano RF. The challenge of viral reservoirs in HIV-1 infection. Annu Rev Med 2002;53:557-593.
17. Groothuis DR, Levy RM. The entry of antiviral and antiretroviral drugs into the central nervous system. J Neurovirol 1997;3:387-400.
18. Kim RB, Fromm MF, Wandel C, et al. The drug transporter P-glycoprotein limits oral absorption and brain entry of HIV-1 protease inhibitors. J Clin Invest 1998;101:289-294.
19. Tyor WR, Power C, Gendelman HE, Markham RB. A model of human immunodeficiency virus encephalitis in scid mice. Proc Natl Acad Sci U S A 1993;90:8658-8662.
20. Persidsky Y, Limoges J, McComb R, et al. Human immunodeficiency virus encephalitis in SCID mice. Am J Pathol 1996;149:1027-1053.
21. Avgeropoulos N, Burris G, Ohlandt G, et al. Potential relationships between the presence of macrophages and astrogliosis in SCID mice with HIV encephalitis. J NeuroAIDS 1998;2:1-20.
22. Avgeropoulos N, Kelley B, Middaugh L, et al. SCID mice with HIV encephalitis develop behavioral abnormalities. J Acquir Immune Defic Syndr Hum Retrovirol 1998;18:13-20.
23. Griffin WC, Middaugh LD, Cook JE, Tyor WR. The severe combined immunodeficient (SCID) mouse model of human immunodeficiency virus encephalitis: deficits in cognitive dysfunction. J Neurovirol 2004;10:109-115.
24. Havlir DV, Marschner IC, Hirsch MS, et al. Maintenance antiretroviral therapies in HIV infected patients with undetectable plasma HIV RNA after triple-drug therapy. AIDS Clinical Trials Group Study 343 Team. N Engl J Med 1998;339:1261-1268.
25. Hammer SM, Squires KE, Hughes MD, et al. A controlled trial of two nucleoside analogues plus indinavir in persons with human immunodeficiency virus infection and CD4 cell counts of 200 per cubic millimeter or less. N Engl J Med 1997;337:725-733.
26. Gulick RM, Mellors JW, Havlir D, et al. Treatment with indinavir, zidovudine, and lamivudine in adults with human immunodeficiency virus infection and prior antiretroviral therapy. N Engl J Med 1997;337:734-739.
27. Haorah J, Heilman D, Diekmann C, et al. Alcohol and HIV decrease proteasome and immunoproteasome function in macrophages: implications for impaired immune function during disease. Cell Immunol 2004;229:139-148.
28. Brewster ME, Anderson WR, Webb AI, et al. Evaluation of a brain-targeting zidovudine chemical delivery system in dogs. Antimicrob Agents Chemother 1997;41:122-128.
29. Busidan Y, Shi X, Dow-Edwards DL. AZT distribution in the fetal and postnatal rat central nervous system. J Pharm Sci 2001;90:1964-1971.
30. Medical Economics Data (Firm). Physicians' desk reference: PDR, Edition 52, Oradell, NJ: Medical Economics, 1998:1167, 1625.
31. Vacca JP, Dorsey BD, Schleif WA, et al. L-735,524: an orally bioavailable human immunodeficiency virus type 1 protease inhibitor. Proc Natl Acad Sci U S A 1994;91:4096-4100.
32. Tyor WR, Wesselingh SL, Griffin JW, et al. Unifying hypothesis for the pathogenesis of HIV-associated dementia complex, vacuolar myelopathy, and sensory neuropathy. J Acquir Immune Defic Syndr Hum Retrovirol 1995;9:379-388.
33. Enting RH, Hoetelmans RM, Lange JM, et al. Antiretroviral drugs and the central nervous system. AIDS 1998;12:1941-1955.
34. Doshi KJ, Gallo JM, Boudinot FD, et al. Comparative pharmacokinetics of 3′-azido-3′-deoxythymidine (AZT) and 3′-azido-2′, 3′-dideoxyuridine (AZddU) in mice. Drug Metab Dispos 1989;17:590-594.
35. Brinkman K, Kroon F, Hugen PW, Burger DM. Therapeutic concentrations of indinavir in cerebrospinal fluid of HIV-1-infected patients. Aids 1998;12:537.
36. Fromm MF. Importance of p-glycoprotein at blood-tissue barriers. Trends Pharmacol Sci 2004;25:423-429.
37. Seelamgari A, Maddukuri A, Berro R, et al. Role of viral regulatory and accessory proteins in HIV-1 replication. Front Biosci 2004;9:2388-2413.
38. Maragos WF, Tillman P, Jones M, et al. Neuronal injury in hippocampus with human immunodeficiency virus transactivating protein, Tat. Neuroscience 2003;117:43-53.
39. Nath, A. Human immunodeficiency virus (HIV) proteins in neuropathogenesis of HIV dementia. J Infect Dis 2002;186(suppl 2):S193-S198.